Drug reference
Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency ▶BY SUBCUTANEOUS INJECTION ▶Adult: 30 mg for 1 dose, then 30 mg after 6 hours if required, then 30 mg after 6 hours if required; maximum 3 doses per day
PDF page 327
Ischaemic heart disease. stroke
PDF page 327
Scottish Medicines Consortium (SMC) decisions SMC No. 476/08 The Scottish Medicines Consortium has advised (March 2012) that icatibant (Firazyr ®) is accepted for use within NHS Scotland for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 3293 The All Wales Medicines Strategy Group has advised (June 2018) that icatibant acetate (Firazyr ®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) Respiratory system in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
PDF pages 327, 328
→Appendix 1: icatibant
PDF page 327
▶Common or very common Dizziness. fever. headache. nausea. skin reactions
PDF page 327
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
PDF page 327
Manufacturer advises avoid for 12 hours after administration.
PDF page 327
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Firazyr (Shire Pharmaceuticals Ltd) Icatibant (as Icatibant acetate) 10 mg per 1 ml Firazyr 30mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection P £1,395.00 Conditions affecting sputum viscosity MUCOLYTICS
PDF page 328
30 mg for 1 dose, then 30 mg after 6 hours if
First-line fragment. Read the complete Indications and Dose section above.
PDF page 327
